109 related articles for article (PubMed ID: 4085312)
1. [Influencing factors in the leakage of liposome and arabinoside cytosine (ARA-C) entrapped in liposomes in treatment of L1210 mouse leukemia].
Fu NW
Zhonghua Zhong Liu Za Zhi; 1985 Jul; 7(4):250-3. PubMed ID: 4085312
[TBL] [Abstract][Full Text] [Related]
2. Stealth liposomes: an improved sustained release system for 1-beta-D-arabinofuranosylcytosine.
Allen TM; Mehra T; Hansen C; Chin YC
Cancer Res; 1992 May; 52(9):2431-9. PubMed ID: 1568213
[TBL] [Abstract][Full Text] [Related]
3. Pharmacology of combination chemotherapy of cytosine arabinoside (ara-C) and uracil arabinoside (ara-U) or tetrahydrouridine (THU) against murine leukemia L1210/0 in tumor-bearing mice.
Avramis VI; Powell W
Cancer Invest; 1987; 5(4):293-9. PubMed ID: 3664332
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapeutic efficacy of Nocodazole encapsulated in liposomes on L1210 murine leukemia.
Laduron C; Coune A; Atassi G; Hildebrand J; Ruysschaert JM; Stryckmans P; Brassinne C
Res Commun Chem Pathol Pharmacol; 1983 Mar; 39(3):419-36. PubMed ID: 6190203
[TBL] [Abstract][Full Text] [Related]
5. Therapy of central nervous system leukemia in mice by liposome-entrapped 1-beta-D-arabinofuranosylcytosine.
Hong F; Mayhew E
Cancer Res; 1989 Sep; 49(18):5097-102. PubMed ID: 2766280
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of tumor cell growth in vitro and in vivo by 1-beta-D-arabinofuranosylcytosine entrapped within phospholipid vesicles.
Mayhew E; Papahadjopoulos D; Rustum YM; Dave C
Cancer Res; 1976 Dec; 36(12):4406-11. PubMed ID: 187321
[TBL] [Abstract][Full Text] [Related]
7. Design of liposomes to improve delivery of macrophage-augmenting agents to alveolar macrophages.
Fidler IJ; Raz A; Fogler WE; Kirsh R; Bugelski P; Poste G
Cancer Res; 1980 Dec; 40(12):4460-6. PubMed ID: 7002293
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of a water-insoluble compound entrapped in liposomes on L1210 leukemia in mice.
Brassinne C; Atassi G; Frühling J; Penasse W; Coune A; Hildebrand J; Ruysschaert JM; Laduron C
J Natl Cancer Inst; 1983 Jun; 70(6):1081-6. PubMed ID: 6574278
[TBL] [Abstract][Full Text] [Related]
9. Effect of 3-deazauridine on the metabolism, toxicity, and antitumor activity of azacitidine in mice bearing L1210 leukemia sensitive and resistant to cytarabine.
Li ZR; Campbell J; Rustum YM
Cancer Treat Rep; 1983 Jun; 67(6):547-54. PubMed ID: 6190558
[TBL] [Abstract][Full Text] [Related]
10. Effect of cholesterol content on antitumor activity and toxicity of liposome-encapsulated 1-beta-D-arabinofuranosylcytosine in vivo.
Ganapathi R; Krishan A; Wodinsky I; Zubrod CG; Lesko LJ
Cancer Res; 1980 Mar; 40(3):630-3. PubMed ID: 7471083
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy of L1210 leukemia with 5-azacytidine in combination with vincristine, adriamycin, or beta-cytosine arabinoside.
Presant CA; Vietti TJ; Valeriote F; Coulter DM
J Natl Cancer Inst; 1981 Dec; 67(6):1283-8. PubMed ID: 6171666
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugated with polyglutamic acid and its derivative.
Kato Y; Saito M; Fukushima H; Takeda Y; Hara T
Cancer Res; 1984 Jan; 44(1):25-30. PubMed ID: 6197162
[TBL] [Abstract][Full Text] [Related]
13. Distribution and metabolism of lipsome-encapsulated and free 1-beta-D-arabinofuranosylcytosine (Ara-C) in dog and mouse tissues.
Ellens H; Rustum Y; Mayhew E; Ledesma E
J Pharmacol Exp Ther; 1982 Aug; 222(2):324-30. PubMed ID: 7097552
[TBL] [Abstract][Full Text] [Related]
14. Role of cholesterol in enhancing the antitumor activity of cytosine arabinoside entrapped in liposomes.
Mayhew E; Rustum YM; Szoka F; Papahadjopoulos D
Cancer Treat Rep; 1979; 63(11-12):1923-8. PubMed ID: 526925
[No Abstract] [Full Text] [Related]
15. Treatment of murine L1210 lymphoid leukemia and melanoma B16 with lipophilic cytosine arabinoside prodrugs incorporated into unilamellar liposomes.
Rubas W; Supersaxo A; Weder HG; Hartmann HR; Hengartner H; Schott H; Schwendener R
Int J Cancer; 1986 Jan; 37(1):149-54. PubMed ID: 3941019
[TBL] [Abstract][Full Text] [Related]
16. Paradoxical effect of cytosine arabinoside on mouse leukemia cell line L1210 cells.
Nakayama T; Sakamoto S; Sassa S; Suzuki S; Kudo H; Nagasawa H
Anticancer Res; 2005; 25(1A):157-60. PubMed ID: 15816533
[TBL] [Abstract][Full Text] [Related]
17. Role of liposome type and route of administration in the antitumor activity of liposome-entrapped 1-beta-D-arabinofuranosylcytosine against mouse L1210 leukemia.
Rustum YM; Dave C; Mayhew E; Papahadjopoulos D
Cancer Res; 1979 Apr; 39(4):1390-5. PubMed ID: 421223
[No Abstract] [Full Text] [Related]
18. Antitumor activity of prolonged-release derivative of cytosine arabinoside, cytosine arabinoside-agarose conjugate.
Hashida M; Kojima T; Muranishi S; Sezaki H
Gan; 1978 Dec; 69(6):839-43. PubMed ID: 750275
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of anti-tumor activity of 1-beta-D-arabinofuranosylcytosine by encapsulation in liposomes.
Kobayashi T; Kataoka T; Tsukagoshi S; Sakurai Y
Int J Cancer; 1977 Oct; 20(4):581-7. PubMed ID: 914397
[TBL] [Abstract][Full Text] [Related]
20. Comparison of lymphatic uptake, metabolism, excretion, and biodistribution of free and liposome-entrapped [14C]cytosine beta-D-arabinofuranoside following intraperitoneal administration to rats.
Parker RJ; Priester ER; Sieber SM
Drug Metab Dispos; 1982; 10(1):40-6. PubMed ID: 6124381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
